T 1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?

There is growing evidence for the accumulation of gadolinium (Gd) in patients administered with intravenous Gd-based contrast agents, even in the absence of renal impairment. This review of the literature will discuss what has been found to date in cadaveric human studies, clinical studies of patien...

Full description

Saved in:
Bibliographic Details
Published in:British journal of radiology 2017-01, Vol.90 (1069), p.20160590
Main Authors: Hoggard, Nigel, Roditi, Giles H
Format: Article
Language:English
Subjects:
Animals
Brain - drug effects
Contrast Media - pharmacokinetics
Gadolinium DTPA - administration & dosage
Gadolinium DTPA - pharmacokinetics
Humans
Image Enhancement - methods
Magnetic Resonance Imaging - adverse effects
Magnetic Resonance Imaging - methods
Neuroimaging - adverse effects
Neuroimaging - methods
Patient Safety
Risk Assessment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is growing evidence for the accumulation of gadolinium (Gd) in patients administered with intravenous Gd-based contrast agents, even in the absence of renal impairment. This review of the literature will discuss what has been found to date in cadaveric human studies, clinical studies of patients and from animal models. Evidence for the potential route of entry into the brain will be examined. The current state of knowledge of effects of Gd accumulation in the brain is discussed. We will then discuss what the possible implications may be for the choice of Gd-based contrast agents in clinical practice.
ISSN:0007-1285
1748-880X
DOI:10.1259/bjr.20160590